S
tatins are commonly used in adults aged 75 years or older (1) . Despite their widespread use, evidence for their effectiveness for primary prevention in elderly adults is unclear, and guidelines for their use in this population are inconsistent. The recently published American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults gave limited recommendations for statin use for primary prevention in adults aged 75 years or older (2) , noting that "few data were available to indicate an atherosclerotic cardiovascular disease event reduction benefit in primary prevention among individuals >75 years of age who do not have clinical year atherosclerotic cardiovascular disease," and suggesting that comorbid conditions, safety, and priorities of care are recommended for joint provider and patient decision making. The American Medical Directors Association, a professional group of long-term care providers, recommended that statins not be routinely prescribed in adults aged 70 years or older as part of the American Board of Internal Medicine Choosing Wisely campaign (3) . This recommendation was based on the lack of an association between high cholesterol levels and outcomes in older adults as well as the potential for an increased risk for statin-related adverse events, including cognitive impairment, falls, neuropathy, and muscle damage (3) .
The variation in these treatment recommendations reflects uncertainty about the balance between the benefits and risks of statin use in older adults compared with younger adults as well as the more limited evidence base in this population. Adults aged 75 years or older have been underrepresented in trials of statins for primary prevention, so the effectiveness of statins is less clear in this population. Results from observational studies suggest that the associations between lowdensity lipoprotein (LDL) cholesterol levels and outcomes are attenuated in older adults (4 -7) . Although the baseline risk for cardiovascular disease is increased in older adults, their life expectancy is shorter and their risks for competing mortality are greater. Finally, there has been concern about geriatric-specific adverse effects, especially functional limitation due to muscle pain, weakness, and mild cognitive impairment (8 -16) .
In the presence of uncertainty about the riskbenefit tradeoff, computer simulations can provide estimates of the potential benefits of various treatment strategies as well as the costs and potential risk for harms. We evaluated the population benefit and costeffectiveness of statins in persons aged 75 years or older without a history of cardiovascular disease in the United States. This investigation was conducted using the Cardiovascular Disease Policy Model (CVDPM), a Markov model of the U.S. population (17) . We simulated the impact of statins for primary prevention based on treatment of the high-risk groups identified by the ACC/AHA guidelines, the associated costs, and potential harms that could offset the potential cardiovascular benefits in the U.S. population of adults aged 75 to 94 years over the next 10 years.
METHODS

The Model
The CVDPM is an established state-transition (Markov) model of the incidence, prevalence, mortality, and cost of CHD and stroke in U.S. residents aged 35 to 94 years (17) . The present study was limited to adults aged 75 to 94 years. The model comprises 3 components. First, the demographic-epidemiologic submodel estimates the incidence of coronary heart disease (CHD) (cardiac arrest, myocardial infarction [MI] , angina, or CHD death), ischemic stroke, and death from other causes on the basis of age, sex, systolic blood pressure, smoking, high-density lipoprotein and LDL cholesterol levels, diabetes, body mass index, and statin use. Second, the bridge submodel characterizes the initial CHD or stroke event and related events in the subsequent 30 days. Third, the disease-history submodel predicts the number of subsequent CHD and stroke events, revascularization procedures, and deaths among patients with cardiovascular disease, stratified according to age, sex, and history of cardiovascular disease events. In addition, persons may exit the model at any stage through a non-CHD, nonstroke mortality function, allowing for competing risk. Modifiable components of the model include population distributions, risk factor levels, risk factor coefficients, event rates, case-fatality rates, costs, and disability adjustments (17) . Costs for stroke requiring hospitalization, CHD, and acute stroke rehabilitation were estimated using California hospital data (18) and were deflated using costcharge ratios and the ratio of the U.S. national average costs to the California average (19, 20) . Age-and sexspecific background health care costs were estimated using national data (21) . All model costs were inflated to 2014 costs by using the medical component of the Consumer Price Index (22) . All disability weights associated with the CHD and stroke event states were based on the Global Burden of Disease Study (23, 24) . Additional details are provided in the Appendix (available at www.annals.org).
Simulation Inputs
We modeled the effect of statins on LDL cholesterol level based on PROSPER (Prospective Study of Pravastatin in the Elderly at Risk of Vascular Disease), a randomized, placebo-controlled trial of 5804 men and women aged 70 to 82 years (25) . In that trial, the mean reduction in LDL cholesterol level was 34% for participants with an average initial level of 147 mg/dL, consistent with the estimated effect of a moderate-dose statin in the 2013 ACC/AHA guideline (2). We included 3 estimates for the effectiveness of a decrease in LDL cholesterol level on events. The primary estimates were derived by extrapolating the age-stratified effect sizes of a 1.0-mmol/L reduction in LDL cholesterol level from the Cholesterol Treatment Trialists' meta-analysis (26) . We fit a regression line to the 3 age strata reported in that analysis (≤60 years, >60 to ≤70 years, and >70 years) to estimate the effect sizes at ages 80 and 90 years. In a sensitivity analysis, we used a high estimate based on the age-pooled estimate of effect of a 1.0-mmol/L reduction in LDL cholesterol level on major coronary events in the meta-analysis. We used a low estimate based on the effect size from PROSPER for primary prevention (25) . Statin costs were derived from the National Average Drug Acquisition Cost (NADAC) database (27). Our primary cost estimate ($5.59 for a 30-day supply) was the average of the NADAC costs for the 4 moderate-dose statins that are available in generic form: atorvastatin, 10 mg; simvastatin, 20 mg; pravastatin, 40 mg; and lovastatin, 40 mg. This cost estimate was $5.00 when indexed to 2010 dollars based on the medical component of the Consumer Price Index (22) . In addition, we used a low cost estimate of $4 per month, based on the price of generic statins from multiple discount retailers (such as Walmart, Target, and Walgreens). For a high cost estimate, we used $30 for a
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Statins for Primary Prevention in U.S. Adults Aged 75 Years or Older 30-day supply; the low and high cost estimates have been used similarly in other contemporary costeffectiveness analyses (28, 29) . Adults aged 65 years or older use a median of 4 medications; therefore, we estimated the cost of an additional 0.25 physician visit per year for statin use, assuming that medication management could be covered in 1 visit (30, 31). We estimated 1 lipid panel per year for monitoring (32). Event rates for myopathy and hemorrhagic stroke were estimated as 0.001 per statin-year of use, based on the ACC/AHA guideline statement (2) .
Although many major and minor adverse effects have been reported to be associated with statin use, we focused on 2 that are important to geriatric populations and that have generated concern in the scientific literature: functional limitation due to muscle pain and weakness, and mild cognitive impairment (8 -16) . Both are prevalent in older adults and can have a substantial effect on quality of life and the ability to live independently. A recent review of late-life activity limitations in the United States reported data on participants in 5 nationally representative surveys. The prevalence of limitations in activities of daily living was 27% in adults aged 75 to 84 years and 45% in those aged 85 years or older (33). The population-weighted average of these estimates is 32% for adults aged 75 to 94 years. Widely varying prevalence estimates for mild cognitive impairment have been reported due to the differential measures of this condition and the differences between populations. A recent review reported prevalence of mild cognitive impairment of 19% to 28% in studies of older U.S. adults; we used the average of the 4 U.S. studies, which was 25% (34). Disability-adjusted lifeyears for the corresponding states were calculated as 1 minus the disability weights reported in the Global Burden of Disease Study (24) . Because the statinassociated relative risk for these adverse effects is uncertain, we assumed no elevated risk for these adverse effects in our base-case scenario. The goal of this investigation was not to evaluate the strength of the literature regarding the presence of these adverse effects but to identify the magnitude of the potential effects required to offset the cardiovascular benefit. In sensitivity analyses, we estimated the magnitude of this relative risk by using the following equation: [(P AE × RR AE ) Ϫ P AE ] × DALY AE = DALY loss, where P AE equals the prev- alence of the adverse effects in the population, RR AE equals the relative risk for the adverse effects associated with statin use, DALY AE equals the disabilityadjusted life-year decrement of the adverse effects, and DALY loss equals the total disability-adjusted life-year decrement per statin-year of use. The total disability-adjusted life-year decrement per statin-year of use was varied from zero to 0.01.
Simulations
We used the CVDPM to run a 10-year simulation of U.S. adults aged 75 to 94 years in 2014 and followed through 2023. We modeled an open cohort, which allowed younger persons to age into the population. We did not model treatment among the few who reached age 95 years because data are insufficient to model cardiovascular disease in adults aged 95 years or older. We first conducted a simulation to estimate the effect of statin use for secondary prevention by modeling the addition of a statin in all adults aged 75 to 94 years who had a history of cardiovascular disease and were not currently using a statin; we assumed the current rate of statin use for older adults without a history of cardiovascular disease. Subsequently, we conducted simulations to compare the effect of primary prevention of the 3 remaining groups identified in the ACC/AHA guidelines: persons with an LDL cholesterol level of at least 4.91 mmol/L (≥190 mg/dL), those with diabetes, and those with a 10-year cardiovascular disease risk of at least 7.5%. Ten-year cardiovascular disease risk was assessed by using the 2013 ACC/AHA cardiovascular risk equation (35) . We also explored the potential effect of statins for primary prevention by using 2 alternative LDL cholesterol thresholds: 4.14 mmol/L (160 mg/dL) or greater and 3.36 mmol/L (130 mg/dL) or greater.
In a sensitivity analysis, we extended follow-up for an additional 10 years (from 2024 to 2033) to evaluate the primary prevention strategies beyond the initial inception years. We conducted sensitivity analyses of both high and low estimates of effectiveness and analyses that used a high and low cost estimate and the effect of no or 1 physician visit per year. We further explored the statin-associated reduction in qualityadjusted life-years required to offset the cardiovascular disease benefit of statin use by varying the reduction from 0 to 0.01. Finally, we used probabilistic sensitivity analyses to vary the effectiveness parameters (LDL cholesterol-reducing effect of statins and the ␤-coefficient on risk for CHD for a 1-mg/dL reduction in LDL cholesterol level) over the range observed in the published literature ( Table 1) . 
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Costs were calculated from the health care system perspective. All costs were inflated to 2014 dollars by using the medical component of the Consumer Price Index (22) . Costs and disability-adjusted life-years were discounted at 3% per year. An intervention was defined as high-value if the cost to extend 1 disability-adjusted life-year was less than $50 000, intermediate-value if the cost was $50 000 to less than $150 000, and lowvalue if the cost was at least $150 000 (36) .
Role of the Funding Source
Funding for this study was provided by the American Heart Association Western States Affiliate and the National Institute on Aging, which had no role in the study design or conduct or the reporting of data. The Institutional Review Board at Oregon State University determined that this study does not meet the definition of "research involving human subjects."
RESULTS
In 2014, an estimated 19 million adults in the United States were aged 75 to 94 years, and 30% had cardiovascular disease. Over the ensuing 10 years, at current rates of statin use, this population was projected to have 2.5 million MIs and 3.1 million CHD deaths and accrue cardiovascular disease costs of $881 billion (Tables 2 and 3) . If all adults aged 75 to 94 years with a history of cardiovascular disease who were not currently using a statin were treated with a statin over the next 10 years, approximately 53 000 MIs and 85 000 CHD deaths would be prevented, an estimated 269 000 disability-adjusted life-years would be gained, and the societal costs of cardiovascular disease would decrease by approximately $14 billion.
The potential effect of statins for primary prevention varied by treatment strategy. All adults aged 75 to 94 years in NHANES (National Health and Nutrition Examination Survey) have an estimated 10-year cardiovascular disease risk of at least 7.5%, so treatment based on this risk threshold does not discriminate in this population. Adding a statin in currently untreated adults aged 75 to 94 years with an LDL cholesterol level of at least 4.91 mmol/L (≥190 mg/dL) was projected to be cost-saving but would have a minimal impact on prevention of MIs and CHD deaths in the overall population because this risk group comprises a small proportion of the population (Tables 2 and 3) . Decreasing the LDL cholesterol treatment threshold to 4.14 mmol/L (160 mg/dL), which was also projected to be costsaving, would allow for treatment of substantially more elderly adults, and the number of events prevented would increase accordingly. At a threshold of 3.36 mmol/L (130 mg/dL), more than 3 million currently untreated older adults would receive statins for primary The value of the statin-associated DALY reduction at which the lines cross the x-axis is the magnitude needed to offset the cardiovascular benefit and result in no net DALYs gained. DALY = disability-adjusted life-year; LDL-C = low-density lipoprotein cholesterol. prevention, and this strategy would prevent 56 000 MIs and 36 000 CHD deaths and would save 108 000 disability-adjusted life-years at an estimated costeffectiveness of $5300 per disability-adjusted year of life compared with a threshold of 4.14 mmol/L (160 mg/dL). Treatment of all diabetic patients was dominated by extension and would not be considered a cost-effective alternative to the other strategies presented. If all older adults who had no history of cardiovascular disease and were not currently using statins were treated, statin use in these nearly 8 million new users would prevent about 105 000 MIs and 68 000 CHD deaths and save 197 000 disability-adjusted lifeyears at an incremental cost per disability-adjusted lifeyear of $25 200 compared with treatment at a threshold of 3.36 mmol/L (130 mg/dL). When the population was stratified by age and sex, all primary prevention strategies were cost-saving or high-value in men and women aged 75 to 84 years and 85 to 94 years compared with secondary prevention alone. Almost all primary prevention strategies were cost-saving in men, and all strategies were high-value in women compared with secondary prevention (Table 4). In the second decade of implementation of these statin therapy strategies (2024 to 2033), secondary prevention was projected to no longer be costsaving but continued to be high-value. In addition, the incremental cost-effectiveness ratios between primary and secondary prevention were modestly attenuated ( Table 5) .
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The benefit observed in the primary prevention strategies was sensitive to assumptions about the magnitude of potential harms. Based on a strategy of treating persons with an LDL cholesterol level of at least 4.91 mmol/L (≥190 mg/dL), the magnitude of the statin-associated disability-adjusted life-year reduction necessary to offset the cardiovascular benefit would be 0.006 (Figure) . Of note, the magnitude of a statinassociated disability-adjusted life-year reduction required to offset the cardiovascular benefit would be smaller for the other primary prevention strategies (Figure) . This reduction translated to relative risks that ranged from 1.10 to 1.24 for functional limitation and from 1.12 to 1.29 for mild cognitive impairment ( Table 6) .
One-way sensitivity analyses showed that the costeffectiveness ratios of the primary prevention strategies were sensitive to effectiveness and cost estimates for statins ( Table 7) . At a lower estimate of effectiveness or a statin cost of $30 per month, treating only adults with an LDL cholesterol level of at least 4.91 mmol/L (≥190 mg/dL) continued to be high-value. In contrast, if effectiveness of statins in adults aged 75 years or older was similar to that observed in a younger population or if older adults were able to obtain statins for $4 per month, all primary prevention strategies were costsaving or very-high-value.
Based on probabilistic sensitivity analyses, the findings for the primary prevention strategies seemed consistent. Compared with treating adults with a history of cardiovascular disease only, treating those with an LDL cholesterol level of at least 4.91 mmol/L (≥190 mg/dL) was projected to prevent 8000 MIs (95% CI, 6000 to 11 000), treating those with an LDL cholesterol level of at least 4.14 mmol/L (≥160 mg/dL) was projected to prevent 26 000 MIs (CI, 17 000 to 35 000), treating 
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Statins for Primary Prevention in U.S. Adults Aged 75 Years or Older those with an LDL cholesterol level of at least 3.36 mmol/L (≥130 mg/dL) was projected to prevent 56 000 MIs (CI, 39 000 to 74 000), treating those with diabetes was projected to prevent 29 000 MIs (CI, 22 000 to 37 000), and treating all was projected to prevent 105 000 MIs (CI, 75 000 to 135 000). Of the primary prevention strategies, 70% of the simulations for treating adults at an LDL cholesterol threshold of 4.91 mmol/L (190 mg/dL), 51% of the simulations for a threshold of 4.14 mmol/L (160 mg/dL), 32% of the simulations for a threshold of 3.36 mmol/L (130 mg/dL), and 21% of the simulations for treating all adults were cost-saving, and 99%, 94%, 83%, and 81%, respectively, were high-value, with a cost per disabilityadjusted life-year less than $50 000.
DISCUSSION
On the basis of available data, we project that generic statins are cost-effective for primary prevention in adults aged 75 to 94 years, and strategies that treat a greater proportion of the population have the potential to prevent similarly higher numbers of MIs and CHD deaths. Although these findings are promising, even a small increased risk for functional limitation or cognitive impairment could offset the cardiovascular benefit. In addition, our estimates of the value of statin use for primary prevention were susceptible to varying assumptions about effectiveness and cost. Because of the sensitivity of our findings to these parameters, studies to quantify the potential benefits and harms of statin use in older adults are paramount.
The ACC/AHA guideline recommends patientprovider discussion of the potential benefits, risk for adverse effects, and patient preferences before statin initiation for primary prevention. In the absence of clear evidence, individualized treatment decision making is warranted. However, for treatment decisions that are vulnerable to variations in effectiveness, cost, and potential risks, more precise and reliable data on these parameters are needed to inform the decision process. Whereas effectiveness data are available from clinical trials, fewer systematic data exist on the potential risks of statins. Clinical trials are likely to include participants who are healthier than those in the general population, so the risks of an intervention in a representative patient population are uncertain. In addition, mild to moderate adverse effects may be underreported in postmarketing surveillance systems intended to identify rare and serious adverse events. We focused on functional limitation due to muscle pain and weakness and mild cognitive impairment because these conditions are prevalent in older adults and can have an important and immediate effect on quality of life and independence (8 -16) . Unlike previous analyses that showed that a large theoretical increase in adverse effects would be required to counterbalance the cardiovascular benefits in the general population (28) , our analysis showed that, in older adults, even a small increase in the risk for functional limitation and mild cognitive impairment from statins could result in net harm. In our simulations, a 10% to 30% increased risk for these adverse effects would offset the cardiovascular benefit. Our results provide strong motivation for further investigations into the incidence of adverse effects from statins in a diverse group of elderly adults, including those who are frail and have complex comorbidity. Because of the sample size required to identify potential risks in a diverse population, pragmatic trials and improved postmarketing surveillance are the most promising approaches for this goal.
We focused on geriatric-specific conditions with an immediate impact on quality of life, although other potential harms and benefits have been considered. Serious adverse effects, including rhabdomyolysis, liver failure, and peripheral neuropathy, seem to be rare (37) , and prior simulations have suggested that the rarity of these events results in a risk-benefit ratio that favors statin use (28, 38, 39) . The risk for statin-associated diabetes is modest (37, 39) , and the time interval from the incidence of diabetes to a clinically observable event is generally delayed and may be less concerning in older adults than the immediate risk for a coronary event. We also did not include the potential benefit of statins on kidney function and peripheral arterial disease because, as with diabetes, the time interval between the incidence of these conditions and a clinically observable event is likely to be several years. Our results underscore both the tremendous potential benefit of statin use and the tenuous balance of benefits and harms and highlight the need to quantify and adequately account for all health effects of the use of these medications for primary prevention in older adults. The CVDPM is tested and updated regularly to reflect changes in risk factor distributions, population estimates, risk factor associations, event rates, casefatality rates, and costs. However, projections from any forecasting model should be viewed with caution because unpredicted changes can impact results. Our projections have limitations that should be considered during interpretation of the findings. The primary limitation, as has been noted by professional groups, is the lack of high-quality evidence targeting primary prevention in adults aged 75 years or older. We used the best available evidence for our simulations and provide high-and low-effect sensitivity analyses. We used pharmaceutical cost data for generic statins; the costeffectiveness of statin use may be substantially lower if older adults use newer agents that have yet to become generic. In addition, pleiotropic or beneficial effects of statins on kidney function or peripheral arterial disease or a harmful effect on diabetes risks could alter our estimates of the benefit-harm ratio.
In summary, statins are projected to be costeffective for primary prevention of cardiovascular disease in a population of adults aged 75 to 94 years that derives a relative benefit similar to what was observed in randomized, controlled trials if a low monthly cost of statins is assumed. More research on effectiveness and potential harms in a diverse population of elderly adults is needed to inform decision making in populations of older adults who are frail or have multiple chronic health conditions. Because even a modest increase in harm could offset the cardiovascular benefit in some populations, large studies of statin users are needed to identify the magnitude of any statinassociated risks. Given the growing population of older adults, the heterogeneity of their health requirements and care goals, and the critical need to give patients and providers tools to make health care decisions that balance potential benefits and potential harms, studies that leverage existing infrastructure may prove most useful for providing these important data in a timely manner. ious complementary sources (58 -60) . Prehospital arrest deaths were estimated from U.S. Vital Statistics (45), and patients with out-of-hospital cardiac arrests who survived to hospital discharge were estimated from national data (56). Survival after a CHD event was estimated using California data on the ratio of inhospital survival to 30-day survival (18) and data from Medicare and Seattle, Washington (61, 62) . Rates of coronary revascularization were estimated from the National Hospital Discharge Survey (56), with mortality rates estimated from aggregated historical data.
Stroke incidence was assumed to be independent of the risk for new-onset CHD in the same year. The number of strokes requiring hospitalization was also obtained from the 2010 NHDS. Positive predictive values of specific ICD-9 stroke hospital diagnosis codes (430 to 438) were derived by pooling several studies of stroke incidence that compared hospital diagnoses with a gold standard (such as stroke ascertained by the Atherosclerosis Risk in Communities Study, the Rochester Epidemiology Study, or similar criteria) (63) . The positive predictive values were applied to age-and sexspecific NHDS cases to estimate total stroke event rates (inclusive of first-ever and recurrent stroke events). Applying 30-day case-fatality rates based on the Atherosclerosis Risk in Communities Study (64, 65) yielded annual mortality rate estimates within the range of stroke rates reported by the Centers for Disease Control and Prevention for 2010. Incidence calibration assumed that 77% of all strokes are incident (first-ever) (66) but that the proportion of first-ever strokes diminished with age (that is, >90% of all strokes are first strokes in persons aged 35 to 44 years and 50% are first strokes in those aged 85 to 94 years). The resulting incidence of stroke requiring hospitalization approximated age-and sex-specific stroke incidence rates observed in U.S. stroke cohort and surveillance studies. The annual probabilities of stroke after MI (67) and the probability of CHD in patients with stroke were based on natural history studies (68 -73) .
The background prevalence of CVD by age, sex, and CVD disease state (stroke, CHD, or both) in 2010 was estimated from National Health Interview Survey data from 2009 to 2011 (74), with the assumption that the imperfect positive predictive value of survey data is offset by its imperfect sensitivity (75-77). Age-specific prevalences for individual CVD disease states were fitted with polynomial or spline functions of age to obtain smooth, monotonically increasing prevalence. The background prevalence of prior coronary revascularization was estimated from revascularizations done before 2010 and estimated survival after revascularization, and model projections were used to infer the distribution of revascularization by CVD state.
Age-and sex-specific health care costs were estimated using national data (21) . Costs for stroke requiring hospitalization, CHD, and acute stroke rehabilitation were estimated by using California hospital data (18) and were deflated using cost-charge ratios and the ratio of the U.S. national average costs to the California average (19, 20) . Outpatient costs for chronic CVD in addition to average background health care costs for the first year after the event and for subsequent years were estimated for patients with stroke or CHD diagnosis surveyed in the U.S. Medical Expenditure Panel Survey (MEPS) pooled from 1998 to 2008. Average annual noncardiovascular (background) costs were also estimated from the MEPS (78). All model costs were indexed to 2010 by using the medical component of the Consumer Price Index (22) . Disability weights and severity distributions for disease states were based on the Global Burden of Disease disability weights study (23, 24, 79, 80) . Individual 10-year atherosclerotic cardiovascular disease risk was assessed by using the 2013 ACC/AHA cardiovascular risk equation (35) .
